Analyst Price Targets — LFMD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 12, 2026 2:07 pm | Ilya Zubkov | Loop Capital Markets | $10.00 | $3.88 | StreetInsider | LifeMD Inc (LFMD) PT Raised to $10 at Freedom Capital Markets |
| November 24, 2025 7:41 pm | Ilya Zubkov | Loop Capital Markets | $8.00 | $3.97 | StreetInsider | LifeMD Inc (LFMD) PT Lowered to $8 at Freedom Capital Markets |
| November 19, 2025 1:33 pm | Steven Valiquette | Mizuho Securities | $6.00 | $3.99 | TheFly | LifeMD price target lowered to $6 from $8 at Mizuho |
| November 19, 2025 11:31 am | Scott Schoenhaus | KeyBanc | $8.00 | $3.99 | TheFly | LifeMD price target lowered to $8 from $12 at KeyBanc |
| November 18, 2025 11:49 am | — | BTIG | $10.00 | $4.09 | TheFly | LifeMD price target lowered to $10 from $18 at BTIG |
| July 10, 2025 12:46 pm | Brooks O'Neil | Lake Street | $18.00 | $11.81 | TheFly | LifeMD price target raised to $18 from $12 at Lake Street |
| March 12, 2025 10:11 am | Yi Chen | H.C. Wainwright | $14.00 | $5.58 | TheFly | LifeMD price target raised to $14 from $12 at H.C. Wainwright |
| January 8, 2025 12:05 pm | Scott Schoenhaus | KeyBanc | $7.00 | $5.54 | TheFly | LifeMD price target lowered to $7 from $10 at KeyBanc |
| December 10, 2024 12:49 pm | Brooks O'Neil | Lake Street | $12.00 | $5.97 | TheFly | LifeMD initiated with a Buy at Lake Street |
| October 14, 2024 2:07 pm | Kyle Bauser | BTIG | $12.00 | $4.64 | StreetInsider | BTIG Reiterates Buy Rating on LifeMD Inc (LFMD) |
Latest News for LFMD
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.
Shares of LifeMD, Inc. (NASDAQ: LFMD - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company.
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth.
LifeMD is rated Buy, trading at a low 0.796x TTM sales, with upside if multiples revert. LFMD's strategic divestment of WorkSimpli refocused the business as a pure-play telehealth and pharmacy provider. The recent launch of the Wegovy pill will expand growth from its GLP-1 vertical.
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LFMD.
U.S. House Trading
No House trades found for LFMD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.